🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Comparative Study of SMILE, ICL, and Wavelight Plus Alcon Technologies in Myopia Correction

RecruitingNAAges 18 Years - 40 YearsAllBeijing Visionly Plus Eye Hospital
NCT06788418 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Myopia is a prevalent refractive error with significant lifestyle impact. While traditional SMILE (Small Incision Lenticule Extraction) and ICL (Implantable Collamer Lens) surgeries are standard options, the advent of the Wavelight Plus Alcon system presents a promising new technique. This trial aims to evaluate the safety, efficacy, and patient satisfaction across these methods.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults aged 18-40 years * Spherical equivalent of -1.00 to -10.00 D * Stable refraction for at least 12 months * Informed consent provided Exclusion Criteria: * Other ocular pathologies * Previous refractive surgery * Pregnancy or nursing * Autoimmune or connective tissue disorders
💊

What it tests

  • Wavelight Plus Alcon system
  • SMILE
  • ICL
📍

Where

2 sites
Beijing New Vision Eye Hospital
Beijing, China
Beijing Visionly Plus Eye Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy